Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

NEEDHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. Program Updates CAN-2409 – Pancreatic Cancer In early April, announced positive updated survival data, from the ongoing randomized phase 2 clinical trial ...